retatrutide type 2 diabetes phase 2 results 2024 2025 🚨 Today, retatrutide, the GIP/GLP-1/glucagon triple agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent obesity and diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Efficacy and safety of retatrutide,

Cardiovascular outcomes (e.g., SELECT and SOUL trials), 2

Tirzepatide microdosing example Strategy A: Titration with smaller increments (compounded version) Tirzepatide come in the form of prefilled pens in fixed, single-use doses (e.g., 2.5 mg, 5 mg, etc.)

its what happens in their head

They used a mouse model of diet-induced obesity and combined metabolomic analyses in BAT and other tissues with stable-isotope tracer studies to answer this question

Retatrutide UK Legal Status Not a controlled substance in the UK Legal to supply for laboratory research purposes Astra Labs fully research-use-only compliant Not approved for human consumption Not a licensed medicine no MHRA authorisation For the full breakdown: Are Peptides Legal in the UK

While SURPASS-4 was not powered to evaluate differences in MACE-4 incidence between tirzepatide treatment groups and glargine, it was designed to fulfill the MACE-4 non-inferiority analysis requested by regulatory authorities to evaluate the cardiovascular safety of new glucose lowering medications